论文部分内容阅读
心房颤动所致脑卒中的致残率和病死率高。和华法林相比，新型口服抗凝药物达比加群酯已被证明预防心房颤动的脑卒中和栓塞安全有效，无需频繁剂量调整和常规监测，使用更为简便。心房颤动患者常合并器质性心脏病，现就达比加群酯在器质性心脏病的心房颤动抗凝治疗中的最新进展进行综述以指导临床治疗。“,”Atrial fibrillation is associated with significant morbidity and mortality related to stroke due to thromboembolism .The useof warfarin reduces the rate of ischemic stroke in patients with atrial fibrillation but requires frequent monitoring and dose adjustment .Dabig-atran etexilate, a new oral anticoagulant , has been approved for the prevention of thromboembolism in patients with non-valvular atrial fibril-lation.Organic heart disease is common in patients with atrial fibrillation .This article summarizes the most recent published data on clinical trials with dabigatran etexilate in atrial fibrillation patients with organic heart disease .